Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

AbbVie (NYSE:ABBV) has agreed to acquire all outstanding equity of neuroscience-focused biotech Aliada Therapeutics for $1.4B ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy ...

A Fierce 15 winner last year, Ventus said its drug, VENT-03, “was safe and well-tolerated at doses far exceeding those planned for use in Phase 2 trials.” The drug’s "favorable PK profile” supports ...

GSK inks agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline: London, UK Thursday, October 31, 2024, 10:00 Hrs [IST] GSK plc and Chimagen Bioscien ...

The TRAILBLAZER-6 trial evaluated the impact of different dosing regimens of Kisunla on the rates of ARIA-E and amyloid clearance in adults with early symptomatic Alzheimer’s di ...

The company has laid off 39% of its staff as it discontinued the development of SPR720 for non-tuberculous mycobacterial ...

GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell-driven autoimmune diseases, for $300m upfront.